litlas
Log inCreate account

Gideon Bollag

Active 1986–2024

73
Papers
29,490
Citations
65
h-index
73
i10-index

Citations

Citations per year for Gideon Bollag1961: 1 citations1987: 7 citations1988: 7 citations1989: 7 citations1990: 4 citations1991: 27 citations1992: 44 citations1993: 77 citations1994: 58 citations1995: 50 citations1996: 85 citations1997: 76 citations1998: 79 citations1999: 124 citations2000: 128 citations2001: 143 citations2002: 120 citations2003: 111 citations2004: 85 citations2005: 186 citations2006: 189 citations2007: 204 citations2008: 212 citations2009: 225 citations2010: 373 citations2011: 410 citations2012: 531 citations2013: 553 citations2014: 477 citations2015: 406 citations2016: 362 citations2017: 389 citations2018: 368 citations2019: 823 citations2020: 935 citations2021: 832 citations2022: 631 citations2023: 452 citations2024: 705 citations2025: 305 citations2026: 9 citations1962–1986: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,206 citing papers, 35.6% of this breakdownChina: 1,092 citing papers, 9.2% of this breakdownUnited Kingdom: 689 citing papers, 5.8% of this breakdownGermany: 678 citing papers, 5.7% of this breakdownItaly: 534 citing papers, 4.5% of this breakdownFrance: 423 citing papers, 3.6% of this breakdownJapan: 403 citing papers, 3.4% of this breakdownAustralia: 338 citing papers, 2.9% of this breakdownCanada: 337 citing papers, 2.9% of this breakdownSpain: 288 citing papers, 2.4% of this breakdownNetherlands: 277 citing papers, 2.4% of this breakdownSwitzerland: 254 citing papers, 2.2% of this breakdown
0%35.6%Other 19.4%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology46.9%
  • Medicine35.3%
  • Immunology and Microbiology6.1%
  • Neuroscience5.4%
  • Computer Science3.4%
  • Chemistry0.9%
  • Other2%

Topics

  • Melanoma and MAPK Pathways7.3%
  • Protein Kinase Regulation and GTPase Signaling3.8%
  • Computational Drug Discovery Methods3.4%
  • Immune cells in cancer2.4%
  • Cancer Mechanisms and Therapy2.1%
  • PI3K/AKT/mTOR signaling in cancer2%
  • Other79%

Coauthors

All papers

Open in search
  1. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model

    Authors: Elizabeth E. Spangenberg, Paul Severson, Lindsay A. Hohsfield, Joshua Crapser, Jiazhong Zhang, Elizabeth A. Burton, Ying Zhang, Wayne Spevak, Jack T. Lin, Nicole Phan, Gaston Habets, Andrey Rymar, Garson Tsang, Jason Walters, Marika Nespi, Parmveer Singh, S Broome, Prabha N. Ibrahim, Chao Zhang, Gideon Bollag, Brian L. West, Kim N. Green - Nature Communications 2019 cited by 998

  2. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

    Authors: Scott M. Wilhelm, Christopher Carter, LiYa Tang, Dean Wilkie, Angela McNabola, Hong Rong, Charles Chen, Xiaomei Zhang, Patrick W. Vincent, Mark McHugh, Yichen Cao, Jaleel Shujath, Susan L. Gawlak, Deepa Eveleigh, Bruce R. Rowley, Li Liu, Lila Adnane, Mark Lynch, Daniel Auclair, I Taylor, Rich Gedrich, Andrei Voznesensky, Bernd Riedl, Leonard Post, Gideon Bollag, Pamela A. Trail - Cancer Research 2004 cited by 4,022

  3. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

    Authors: Poulikos I. Poulikakos, Chao Zhang, Gideon Bollag, Kevan M. Shokat, Neal Rosen - Nature 2010 cited by 1,829

  4. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

    Authors: Gideon Bollag, Peter Hirth, James Tsai, Jiazhong Zhang, Prabha N. Ibrahim, Hanna Cho, Wayne Spevak, Chao Zhang, Ying Zhang, Gaston Habets, Elizabeth A. Burton, Bernice H. Wong, Garson Tsang, Brian L. West, Ben Powell, Rafe Shellooe, Adhirai Marimuthu, Hoa Nguyen, Kam Y. J. Zhang, Dean R. Artis, Joseph Schlessinger, Fei Su, Brian Higgins, Raman Iyer, Kurt D’Andrea, Astrid Koehler, Michael Stumm, Paul Lin, Richard J. Lee, Joseph F. Grippo, Igor Puzanov, Kevin B. Kim, Antoni Ribas, Grant A. McArthur, Jeffrey A. Sosman, Paul B. Chapman, Keith T. Flaherty, Xiaowei Xu, Katherine L. Nathanson, K. B. Nolop - Nature 2010 cited by 1,837

  5. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

    Authors: William D. Tap, Zev A. Wainberg, Stephen P. Anthony, Prabha N. Ibrahim, Chao Zhang, John H. Healey, Bartosz Chmielowski, Arthur P. Staddon, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Arun S. Singh, Igor Puzanov, Eunice L. Kwak, Andrew J. Wagner, Daniel D. Von Hoff, Glen J. Weiss, Ramesh K. Ramanathan, Jiazhong Zhang, Gaston Habets, Ying Zhang, Elizabeth A. Burton, Gary C. Visor, Laura Sanftner, Paul Severson, Hoa Nguyen, Marie J. Kim, Adhirai Marimuthu, Garson Tsang, Rafe Shellooe, C. M. Gee, Brian L. West, Peter Hirth, K. B. Nolop, Matt van de Rijn, Henry H. Hsu, Charles Peterfy, Paul Lin, Sandra Tong-Starksen, Gideon Bollag - New England Journal of Medicine 2015 cited by 582

  6. CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer

    Authors: Jingying Xu, Jemima Escamilla, Stephen Mok, John David, Saul J. Priceman, Brian L. West, Gideon Bollag, William H. McBride, Lily Wu - Cancer Research 2013 cited by 561

  7. Vemurafenib: the first drug approved for BRAF-mutant cancer

    Authors: Gideon Bollag, James Tsai, Jiazhong Zhang, Chao Zhang, Prabha N. Ibrahim, K. B. Nolop, Peter Hirth - Nature Reviews Drug Discovery 2012 cited by 824

  8. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

    Authors: James Tsai, John Tayu Lee, Weiru Wang, Jiazhong Zhang, Hanna Cho, Shumeye Mamo, Ryan Bremer, S. Gillette, Jun Kong, Nikolas K. Haass, Katrin Sproesser, Ling Li, Keiran S.M. Smalley, Daniel W. Fong, Yongliang Zhu, Adhirai Marimuthu, Hoa Nguyen, Billy Lam, Jennifer Liu, Ivana Cheung, Julie Rice, Yoshihisa Suzuki, Catherine A. Luu, Calvin Settachatgul, Rafe Shellooe, John Cantwell, Sung‐Hou Kim, Joseph Schlessinger, Kam Y. J. Zhang, Brian L. West, Ben Powell, Gaston Habets, Chao Zhang, Prabha N. Ibrahim, Peter Hirth, Dean R. Artis, Meenhard Herlyn, Gideon Bollag - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 1,346

  9. Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy

    Authors: Stephen Mok, Richard C. Koya, Christopher Tsui, Jingying Xu, Lídia Robert, Lily Wu, Thomas G. Graeber, Brian L. West, Gideon Bollag, Antoni Ribas - Cancer Research 2013 cited by 318

  10. Hyperactive Ras in developmental disorders and cancer

    Authors: Suzanne Schubbert, Kevin Shannon, Gideon Bollag - Nature reviews. Cancer 2007 cited by 1,586

  11. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation

    Authors: Debyani Chakravarty, Elmer Santos, Mabel Ryder, Jeffrey A. Knauf, Xiao-Hui Liao, Brian L. West, Gideon Bollag, Richard Kolesnick, Tin Htwe Thin, Neal Rosen, Pat Zanzonico, Steven M. Larson, Samuel Refetoff, Ronald Ghossein, James A. Fagin - Journal of Clinical Investigation 2011 cited by 387

  12. RAF inhibitors that evade paradoxical MAPK pathway activation

    Authors: Chao Zhang, Wayne Spevak, Ying Zhang, Elizabeth A. Burton, Yan Ma, Gaston Habets, Jiazhong Zhang, Jack Lin, Todd Ewing, Bernice Matusow, Garson Tsang, Adhirai Marimuthu, Hanna Cho, Guoxian Wu, Weiru Wang, Daniel W. Fong, Hoa Nguyen, Songyuan Shi, Patrick Womack, Marika Nespi, Rafe Shellooe, Heidi Carias, Ben Powell, Emily Light, Laura Sanftner, Jason Walters, James Tsai, Brian L. West, Gary C. Visor, Hamid Rezaei, Paul Lin, K. B. Nolop, Prabha N. Ibrahim, Peter Hirth, Gideon Bollag - Nature 2015 cited by 381

  13. Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases

    Authors: G.L. Card, B.P. England, Yoshihisa Suzuki, Daniel W. Fong, Ben Powell, Byunghun Lee, Catherine A. Luu, M. Tabrizizad, S. Gillette, Prabha N. Ibrahim, Dean R. Artis, Gideon Bollag, Michael V. Milburn, Sung‐Hou Kim, Joseph Schlessinger, Kam Y. J. Zhang - Structure 2004 cited by 431

  14. An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling

    Authors: Zoi Karoulia, Yang Wu, Tamer A. Ahmed, Qisheng Xin, Julien Bollard, Clemens Krepler, Xuewei Wu, Chao Zhang, Gideon Bollag, Meenhard Herlyn, James A. Fagin, Amaia Lujambio, Evripidis Gavathiotis, Poulikos I. Poulikakos - Cancer Cell 2016 cited by 213

  15. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling

    Authors: Zhan Yao, Yijun Gao, Wenjing Su, Rona Yaeger, Jessica J. Tao, Na Na, Ying Zhang, Chao Zhang, Andrey Rymar, Anthony Tao, Neilawattie Merna Timaul, Rory Mcgriskin, Nathaniel A. Outmezguine, HuiYong Zhao, Qing Chang, Besnik Qeriqi, Mariano Barbacid, Elisa de Stanchina, David M. Hyman, Gideon Bollag, Neal Rosen - Nature Medicine 2018 cited by 196

  16. CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy

    Authors: Jemima Escamilla, Shiruyeh Schokrpur, Connie Liu, Saul J. Priceman, Diana Moughon, Ziyue Karen Jiang, Frédéric Pouliot, Clara E. Magyar, James L. Sung, Jingying Xu, Gang Deng, Brian L. West, Gideon Bollag, Yves Fradet, Louis Lacombe, Michael E. Jung, Jiaoti Huang, Lily Wu - Cancer Research 2015 cited by 215

  17. RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

    Authors: Fei Su, Amaya Virós, Carla Milagre, Kerstin Trunzer, Gideon Bollag, Olivia Spleiss, Jorge S. Reis‐Filho, Xiangju Kong, Richard C. Koya, Keith T. Flaherty, Paul B. Chapman, Min Jung Kim, Robert Hayward, Matthew J. Martin, Hong Yang, Qiongqing Wang, Holly Hilton, Julie S. Hang, Johannes Noé, Maryou Lambros, Felipe C. Geyer, Nathalie Dhomen, Ion Niculescu‐Duvaz, Alfonso Zambon, Dan Niculescu‐Duvaz, Natasha Preece, Lídia Robert, Nicholas Otte, Stephen Mok, Damien Kee, Yan Ma, Chao Zhang, Gaston Habets, Elizabeth A. Burton, Bernice H. Wong, Hoa Nguyen, Mark Kockx, Luc Andries, Brian Lestini, K. B. Nolop, Richard J. Lee, Andrew K. Joe, James L. Troy, René González, Thomas E. Hutson, Igor Puzanov, Bartosz Chmielowski, Caroline J. Springer, Grant A. McArthur, Jeffrey A. Sosman, Roger S. Lo, Antoni Ribas, Richard Marais - New England Journal of Medicine 2012 cited by 1,028

  18. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus

    Authors: Peter de Blank, Andrea M. Gross, Srivandana Akshintala, Jaishri O. Blakeley, Gideon Bollag, Ashley Cannon, Eva Dombi, Jason Fangusaro, Bruce D. Gelb, Darren Hargrave, AeRang Kim, Laura J. Klesse, Mignon L. Loh, Staci Martin, Christopher L. Moertel, Roger J. Packer, Jonathan M. Payne, Katherine A. Rauen, Jonathan J. Rios, Nathan Robison, Elizabeth K. Schorry, Kevin Shannon, David A. Stevenson, Elliot Stieglitz, Nicole J. Ullrich, Karin S. Walsh, Brian Weiss, Pamela L. Wolters, Kaleb Yohay, Marielle E. Yohe, Brigitte C. Widemann, Michael J. Fisher - Neuro-Oncology 2022 cited by 101

  19. Germline KRAS mutations cause Noonan syndrome

    Authors: Suzanne Schubbert, Martin Zenker, Sara L. Rowe, Silke Böll, Cornelia Klein, Gideon Bollag, Ineke van der Burgt, Luciana Musante, Vera M. Kalscheuer, Lars‐Erik Wehner, Hoa Nguyen, Brian L. West, Kam Y. J. Zhang, Erik A. Sistermans, Anita Rauch, Charlotte M. Niemeyer, Kevin Shannon, Christian P. Kratz - Nature Genetics 2006 cited by 740

  20. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21

    Authors: George A. Martin, David Viskoohil, Gideon Bollag, Peter C. McCabe, Walter J. Crosier, Heinz Haubruck, Leah Conroy, Robin Clark, P. O’Connell, Richard Cawthon, Michael A. Innis, Frank McCormick - Cell 1990 cited by 1,003

  21. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition

    Authors: Carlos E. Prada, Edwin Jousma, Tilat A. Rizvi, Jianqiang Wu, R. Scott Dunn, Debra A. Mayes, José A. Cancelas, Eva Dombi, Mi‐Ok Kim, Brian L. West, Gideon Bollag, Nancy Ratner - Acta Neuropathologica 2012 cited by 142

  22. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells

    Authors: Gideon Bollag, D. Wade Clapp, Shane Shih, Felix Adler, You Yan Zhang, Patricia Thompson, Beverly J. Lange, Melvin H. Freedman, Frank McCormick, Tyler Jacks, Kevin Shannon - Nature Genetics 1996 cited by 608

  23. Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

    Authors: Muling Mao, Feng Tian, John M. Mariadason, Chun C. Tsao, Robert Lemos, Farshid Dayyani, Y.N. Vashisht Gopal, Zhi-Qin Jiang, Ignacio I. Wistuba, Xi Tang, William G. Bornman, Gideon Bollag, Gordon B. Mills, Garth Powis, Jayesh Desai, Gary E. Gallick, Michael A. Davies, Scott Kopetz - Clinical Cancer Research 2012 cited by 298

  24. A Glutamine Switch Mechanism for Nucleotide Selectivity by Phosphodiesterases

    Authors: Kam Y. J. Zhang, G.L. Card, Yoshihisa Suzuki, David Artis, Daniel W. Fong, S. Gillette, Davin Hsieh, Joshua Neiman, Brian L. West, Chao Zhang, Michael V. Milburn, Sung‐Hou Kim, Joseph Schlessinger, Gideon Bollag - Molecular Cell 2004 cited by 297